Investor Presentation

August 23, 2026 BSE Limited Code: 532321 1st Floor, P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Investor presentation for investor conference Ref.: Our earlier letter dated August 17, 2026 Dear Madam / Sir, In continuation to our earlier letter dated August 17, 2026, please find attached the presentation to be made during the investors’ meet between August 24, 2026, to August 26, 2026. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zydus Lifesciences Limited Corporate Presentation August 2026 85 Disclaimer This presentation is issued by Zydus Lifesciences Limited (the “Company”) for general information purposes only, without regard to specific objectives, suitability, financial situations and needs of any particular person. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefor. No person is authorized to give any information or to make any representation not contained 121 in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future 10 events. This presentation should not be relied upon as a recommendation or forecast by the Company. Please note that the past performance of the Company or its Subsidiaries or its Joint Venture is not, and should not be considered as, indicative of future results. The Company cannot guarantee that these assumptions and expectations are accurate or will be realised. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. This presentation may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of applicable laws. The information contained in these materials has not been independently verified. None of the Company or its Subsidiaries or its Joint Ventures, its Directors or affiliates nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or 112 warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertakes no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation has been prepared for publication in India and is not for publication or distribution, directly or indirectly, in or into the United States. The equity shares of the Company (the “Equity Shares”) have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States absent registration under the U.S. Securities Act or except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under 190 the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (b) outside the United States in “offshore transactions”, as defined in, and in reliance upon, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States. 111 VISION To be a global life-sciences company transforming lives through innovative discoveries 149 MISSION To unlock new possibilities in life-sciences through healthcare solutions that impact lives PURPOSE 190 Empowering people with the 223 freedom to live healthier and 223 more fulfilled lives 85 Zydus Lifesciences: Innovation-led Diversified Lifesciences Company 51 Global Scale and Capabilities Leadership Across Multiple Markets Portfolio and Product Pipeline 12 Leading company in IPM; #1 in Oncology4 121 US$ 3 bn+ US$ 959mn 133 FY26 FY26 Revenue1 EBITDA1 249 US$ 11.7bn US$ 257mn Market FY26 R&D Cap2 Spends1 MedTech 2.9% Consumer Wellness India Formulations 14.6% 117 44 Manufacturing Facilities3 24.6% Others7 2.6% Formulations 244 10 11.5% R&D Centres3 North America 242 Formulations 43.7% Zydans Globally3 (with 1.5k+ Scientists) 1. FY26 average exchange rate of INR 88.33/ US$ 4. AWACS MAT June 2026 7. Others includes API and Alliances 2. As on 21st August 2026 at an exchange rate of INR 95.72/ US$ 5. IQVIA MAT June 26 TRx 8. In Q1FY27; Incl. Pharmaceutical, Wellness & MedTech 4 3. As of 30th June 2026 6. Neilsen & IQVIA MAT June’26 report and company estimates Key Characteristics of our Business Fast-Growing Large Market Markets Potential #3 in the US Gx Market (by prescriptions)5 Entry Barriers IP led Sustainable #1 in 5 out of 7 Key Consumer Wellness brands in India6 Limiting Business Competition FY26 Business Mix Differentiated High Margins Products Specialty Biosimilars FY26 NCEs Portfolio (incl. ADCs) Revenue1 $ 3.02bn Consumer Pharma MedTech Vaccines Wellness >55%: Revenue from Branded Business8 85 Three Large Global Categories 12 Pharma 149 Consumer Wellness 233 MedTech 1. 54.2%, up 360bps over the last four years (Source: AWACS MAT June 2026) 5. 505(b)(2) pipeline, Biosimilars, Rare disease assets, Rolvedon® Acquisition [Showing first 8,000 characters — download PDF for full document]